{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:00:53Z","timestamp":1790805653570,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.eclinm.2024.102516","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T07:58:13Z","timestamp":1709193493000},"page":"102516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study"],"prefix":"10.1016","volume":"70","author":[{"given":"Xibin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-2449","authenticated-orcid":false,"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2024.102516_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102516_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"6382","key":"10.1016\/j.eclinm.2024.102516_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102516_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicenter, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102516_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.eclinm.2024.102516_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102516_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102516_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102516_bib9","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102516_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102516_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/77513","article-title":"Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression","volume":"6","author":"Zhang","year":"2000","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102516_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102516_bib13","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","article-title":"Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"70","key":"10.1016\/j.eclinm.2024.102516_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102516_bib15","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.26564","article-title":"Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study","volume":"97","author":"Tang","year":"2022","journal-title":"Am J Hematol"},{"issue":"27","key":"10.1016\/j.eclinm.2024.102516_bib16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102516_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.eclinm.2024.102516_bib18","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1158\/1078-0432.CCR-23-0916","article-title":"Axicabtagene ciloleucel in combination with the 4\u20131BB agonist utomilumab in patients with relapsed\/refractory large B-cell lymphoma: phase 1 results from ZUMA-11","volume":"29","author":"Jain","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.eclinm.2024.102516_bib19","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"S2","key":"10.1016\/j.eclinm.2024.102516_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hon.3164_389","article-title":"First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed\/refractory (R\/R) B-cell malignancies","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2024.102516_bib21","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A\u00a0phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma Delta1 (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2024.102516_bib22","article-title":"Abstract 5510: preclinical study of allogeneic CD19-CAR-DNT cells as an off-the-shelf immunotherapy drug for NHL","volume":"82","author":"Yang","year":"2022","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102516_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102516_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41467-023-36126-7","article-title":"Enhancing CAR-T cell functionality in a patient-specific manner","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2024.102516_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-138404","article-title":"Detecting 24 kinds of cytokines via flow cytometry aimplex kit is an effective way to monitor CRS after CAR-T cells infusion","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102516_bib26","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102516_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1084\/jem.20020029","article-title":"The immune regulatory function of lymphoproliferative double negative T cells in\u00a0vitro and in\u00a0vivo","volume":"196","author":"Ford","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102516_bib28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4049\/jimmunol.181.4.2271","article-title":"Cutting edge: in\u00a0vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression","volume":"181","author":"Ford McIntyre","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.eclinm.2024.102516_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fimmu.2019.00883","article-title":"Human double-negative regulatory T-cells induce a metabolic and functional switch in effector T-cells by suppressing mTOR activity","volume":"10","author":"Haug","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102516_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/cei.13145","article-title":"Infusion of ex-vivo expanded human TCR-alphabeta(+) double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease","volume":"193","author":"Achita","year":"2018","journal-title":"Clin Exp Immunol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:05:46Z","timestamp":1762632346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":30,"alternative-id":["S2589537024000956"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102516","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102516"}}